Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 3
2003 1
2004 3
2005 2
2006 3
2007 3
2008 4
2009 7
2010 4
2011 2
2012 4
2013 5
2014 5
2015 3
2016 5
2017 5
2018 4
2019 5
2020 6
2021 8
2022 8
2023 13
2024 7
2025 3
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

101 results

Results by year

Filters applied: . Clear all
Page 1
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy.
Mountzios G, Sun L, Cho BC, Demirci U, Baka S, Gümüş M, Lugini A, Zhu B, Yu Y, Korantzis I, Han JY, Ciuleanu TE, Ahn MJ, Rocha P, Mazières J, Lau SCM, Schuler M, Blackhall F, Yoshida T, Owonikoko TK, Paz-Ares L, Jiang T, Hamidi A, Gauto D, Recondo G, Rudin CM; DeLLphi-304 Investigators. Mountzios G, et al. N Engl J Med. 2025 Jul 24;393(4):349-361. doi: 10.1056/NEJMoa2502099. Epub 2025 Jun 2. N Engl J Med. 2025. PMID: 40454646 Clinical Trial.
Predictive value of ENLIGHT-DP in patients with metastatic lung adenocarcinoma treated with immune checkpoint inhibitors and platinum chemotherapy directly from histopathology slides using inferred transcriptomics.
Arnon J, Dinstag G, Tirosh O, Gugel L, Kinar Y, Gottlieb T, Elia A, Rottenberg Y, Nechushtan H, Tabi M, Blumenfeld P, Pikarsky E, Beker T, Aharonov R, Popovtzer A. Arnon J, et al. Among authors: nechushtan h. J Immunother Cancer. 2025 Jan 11;13(1):e010132. doi: 10.1136/jitc-2024-010132. J Immunother Cancer. 2025. PMID: 39800380 Free PMC article.
Tumor analysis of BRCA carriers reveals genomic similarities although separated by time.
Falick Michaeli T, Granit Mizrahi A, Azria B, Maymon O, Rosenberg S, Monin J, Braitbart Cohen E, Maoz M, Kadiuri L, Nechushtan H, Meyrowitz A, Peretz T. Falick Michaeli T, et al. Among authors: nechushtan h. Discov Oncol. 2024 Nov 23;15(1):698. doi: 10.1007/s12672-024-01577-x. Discov Oncol. 2024. PMID: 39579167 Free PMC article.
The functional role of Nudt2 in human triple negative breast cancer.
Abu-Rahmah R, Nechushtan H, Hidmi S, Meirovitz A, Razin E, Peretz T. Abu-Rahmah R, et al. Among authors: nechushtan h. Front Oncol. 2024 Apr 23;14:1364663. doi: 10.3389/fonc.2024.1364663. eCollection 2024. Front Oncol. 2024. PMID: 38715773 Free PMC article.
Outcomes of extracranial stereotactic body radiation therapy for induced oligometastatic non-small cell lung cancer on novel systemic therapy.
Tsur E, Blumenfeld P, Rottenberg Y, Nechushtan H, Arnon J, Wald O, Izhar U, Pfeffer R, Krakow A, Wygoda M, Popovtzer A, Michaeli TF. Tsur E, et al. Among authors: nechushtan h. Transl Lung Cancer Res. 2024 Mar 29;13(3):465-474. doi: 10.21037/tlcr-23-802. Epub 2024 Mar 22. Transl Lung Cancer Res. 2024. PMID: 38601442 Free PMC article.
Plasma Proteome-Based Test for First-Line Treatment Selection in Metastatic Non-Small Cell Lung Cancer.
Christopoulos P, Harel M, McGregor K, Brody Y, Puzanov I, Bar J, Elon Y, Sela I, Yellin B, Lahav C, Raveh S, Reiner-Benaim A, Reinmuth N, Nechushtan H, Farrugia D, Bustinza-Linares E, Lou Y, Leibowitz R, Kamer I, Zer Kuch A, Moskovitz M, Levy-Barda A, Koch I, Lotem M, Katzenelson R, Agbarya A, Price G, Cheley H, Abu-Amna M, Geldart T, Gottfried M, Tepper E, Polychronis A, Wolf I, Dicker AP, Carbone DP, Gandara DR. Christopoulos P, et al. Among authors: nechushtan h. JCO Precis Oncol. 2024 Mar;8:e2300555. doi: 10.1200/PO.23.00555. JCO Precis Oncol. 2024. PMID: 38513170 Free PMC article.
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.
Motzer RJ, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Alekseev B, Rha SY, Merchan J, Goh JC, Lalani AA, De Giorgi U, Melichar B, Hong SH, Gurney H, Méndez-Vidal MJ, Kopyltsov E, Tjulandin S, Gordoa TA, Kozlov V, Alyasova A, Winquist E, Maroto P, Kim M, Peer A, Procopio G, Takagi T, Wong S, Bedke J, Schmidinger M, Rodriguez-Lopez K, Burgents J, He C, Okpara CE, McKenzie J, Choueiri TK; CLEAR Trial Investigators. Motzer RJ, et al. J Clin Oncol. 2024 Apr 10;42(11):1222-1228. doi: 10.1200/JCO.23.01569. Epub 2024 Jan 16. J Clin Oncol. 2024. PMID: 38227898 Free PMC article. Clinical Trial.
101 results